Evidence map›Paper›PMID 41969661›Full record

ArticleFrontiers in cellular and infection microbiology2026

Clinical characteristics and risk factors analysis of

Tingting Xu, Ying Xie

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Tingting XuDepartment of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Ying XieDepartment of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the risk factors for Methods: Patients diagnosed with UC who received Infliximab (IFX) or Vedolizumab (VDZ) were enrolled. Their clinical characteristics and risk factors for CDI were analyzed. Results: A total of 110 UC patients treated with IFX (61 cases) or VDZ (49 cases) were included. The overall positive rate of Conclusion: Positive EBV-DNA, a modified Mayo score ≥11 points, and a history of glucocorticoids use within 2 months before admission were independent risk factors for CDI in UC patients during IFX/VDZ therapy.

Indexed as

Biological TherapyClostridioides difficileClostridium InfectionsColitis, UlcerativeAdultAntibodies, Monoclonal, HumanizedFemaleHerpesvirus 4, HumanHumansIncidenceInfliximabMaleMiddle AgedRisk FactorsAntibodies, Monoclonal, HumanizedInfliximabvedolizumabClostridioides difficile infectionInfliximabrisk factorsulcerative colitisVedolizumab

Identifiers

PMID41969661
PMCPMC13066211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.